Russell T. Wise

Russell T. Wise

Auto-generated profile, based on publicly available information

Russell T. Wise

Department of Pharmacy, Lucile Packard Children’s Hospital Stanford, Palo Alto, California, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2023 in Hepatology Communications
Verified
Journal Article
Open access
SLSteven Levitte
Steven Levitte
YFYonathan Fuchs
Yonathan Fuchs
RWRussell Wise
Russell Wise
ZSZachary M. Sellers
Zachary M. Sellers
The cystic fibrosis (CF) transmembrane conductance regulator corrector/potentiator combinations lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor improve sweat chloride, pulmonary function, and nutrition. Yet it is unclear whether they may also impact the progression of liver fibrosis, which is a substantial source of morbidity and mortality for patients with CF. We conducted a retrospective, single-center analysis of children and adolescents with CF treated with lumacaftor/ivacaftor and/or elexacaftor/tezacaftor/ivacaftor therapy, focusing on alterations in liver function tests and fibrosis indices using previously-established thresholds that corresponded with increased liver elastography. In pairwise comparisons of before and during treatment timepoints, we found that those with CF-associated liver involvement experienced significant decreases in gamma-glutamyl transferase, aspartate aminotransferase-to-platelet index, and gamma-glutamyl transferase-to-platelet ratio while on lumacaftor/ivacaftor. These differences were not observed in patients treated with elexacaftor/tezacaftor/ivacaftor, nor were they observed in patients without underlying CF-associated liver disease. These results provide the first evidence that lumacaftor/ivacaftor may improve liver fibrosis in children and adolescents with CF and suggest it may be beneficial in the treatment of CF-associated liver disease.

22 August 2020 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
JBJake Brockmeyer
Jake Brockmeyer
RWRussell T. Wise
Russell T. Wise
EBElizabeth Burgener
Elizabeth Burgener
CMCarlos Milla
Carlos Milla
AFAdam Frymoyer
Adam Frymoyer